Revised Response Criteria for Malignant Lymphoma
Bruce D. Cheson, Beate Pfistner, Malik E. Juweid, Randy D. Gascoyne, Lena Specht, Sandra J. Horning, Bertrand Coiffier, Richard I. Fisher, Anton Hagenbeek, Emanuele Zucca, Steven T. Rosen, Sigrid Stroobants, T. Andrew Lister, Richard T. Hoppe, Martin Dreyling, Kensei Tobinai, Julie M. Vose, Joseph M. Connors, Massimo Federico, and Volker Diehl
Revised Response Criteria for Malignant Lymphoma. J Clin Oncol. 2007; 25 (5): 579-86.
As with most published assessment criteria, the 1999 IWG-NHL contained some aspects that were unclear which often led to misinterpretation of the authors' intent. Perhaps the best example of this was the often misunderstood CRu (complete response unconfirmed) category.
To remediate these areas of uncertainty, the authors published revised guidelines in 2007. The intent of this new revision was to add clarifications to the 1999 criteria and also to provide guidance based on recent advances in the field.
In essence, the 2007 criteria replaced those published in 1999.
Despite the clarity provided by the revision, the 2007 IWG-NHL guidelines have also been subject to variations in user interpretation.
Following extended discussions with experts in the field, including Dr. Bruce Cheson, PAREXEL Informatics recommends that future clinical trials rely on the 2007 IWG-NHL guidelines with or without FDG-PET. PAREXEL Informatics also recommends incorporating clarifications into the 2007 IWG-NHL guidelines to minimize variation in the interpretation of the criteria. Refer to the key topics below for more information on implementing the 2007 IWG-NHL guidelines in clinical trials.